The next steps for research include a randomized, controlled trial combining TNFi and varying NSAIDs or different doses, Dr. Gensler said. In addition, “the development of newer imaging modalities will allow us to answer these questions in a more feasible time frame.”
The study was not industry funded. Dr. Gensler reported financial relationships with Amgen, AbbVie, Janssen, Eli Lilly, Novartis, and UCB.
SOURCE: Gensler L et al. Ann Rheum Dis. 2018;77(Suppl 2):148. Abstract OP0198.